2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohort
2021
EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
Fineberg S, Tian X, Makower D, Harigopal M, Lo Y. EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis. Applied Immunohistochemistry & Molecular Morphology 2021, 30: 157-164. PMID: 35262520, DOI: 10.1097/pai.0000000000000998.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyEZH2 protein expressionEZH2 expressionBreast cancerHigh-risk triple negative breast cancerLogistic regressionContinuous variablesStratification of outcomesDisease-free survivalProtein expressionTumor-infiltrating lymphocytesHigh EZH2 expressionMultivariable logistic regressionRisk of relapseDevelopment of metastasesLogistic regression analysisPretherapy biopsiesDisease recurrenceMetastatic recurrenceClinicopathologic featuresCancer burdenTumor responseCore biopsyApocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalCancer-specific survivalHigh-grade tumorsMolecular subtypesApocrine carcinomaBreast cancerBetter survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerRare breast cancerEnd Results (SEER) databaseGrowth factor receptor 2Triple-negative patientsTriple-negative cancersLow-grade tumorsFactor receptor 2Life table methodApocrine tumorsLuminal patientsWorse survivalClinicopathologic featuresResults databaseAggressive featuresReceptor 2
2020
LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1
Malvi P, Janostiak R, Chava S, Manrai P, Yoon E, Singh K, Harigopal M, Gupta R, Wajapeyee N. LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis 2020, 9: 77. PMID: 32859889, PMCID: PMC7455732, DOI: 10.1038/s41389-020-00263-1.Peer-Reviewed Original ResearchTriple-negative breast cancerLIM domain kinase 2Metastatic progressionPharmacological inhibitionBreast cancerTNBC cellsMetastatic attributesMetastatic breast cancer subtypesSerine/arginine protein kinasesPrimary tumor growthBreast cancer subtypesKinase 2Serine/threonine kinaseActin filament dynamicsStable isotope labelingShort hairpin RNASystemic therapyProtein kinase 1Therapeutic optionsHER2 expressionLarge-scale phosphoproteomic analysisTNBC metastasisTumor growthCancer subtypesSR familyHigh frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers
Yoon EC, Wilson P, Zuo T, Pinto M, Cole K, Harigopal M. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. Human Pathology 2020, 102: 13-22. PMID: 32565323, DOI: 10.1016/j.humpath.2020.06.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNon-TNBC casesFrequency of p16TNBC casesAndrogen receptorBreast cancerTissue microarrayAggressive clinical courseAndrogen receptor expressionInvasive ductal carcinomaHistologic grade 3Basal-like breast cancer subtypeNovel prognostic markerBreast cancer subtypesExpression of p16Clinical courseCytokeratin 5/6Ductal carcinomaPrognostic markerReceptor expressionRoutine biomarkersSignificant statistical differenceClinical dataGrade 3Cancer subtypes
2018
Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers
Zuo T, Wilson P, Cicek AF, Harigopal M. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers. Human Pathology 2018, 80: 239-245. PMID: 29902579, DOI: 10.1016/j.humpath.2018.06.003.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerDisease-free survivalBasal-like triple-negative breast cancerFavorable prognostic factorAndrogen receptor expressionAR expressionOverall survivalBreast cancerAR positivityPrognostic factorsTumor sizeHistologic gradeReceptor expressionTissue microarrayAR-positive triple-negative breast cancerSubgroups of TNBCAR-negative TNBCLack estrogen receptorBetter overall survivalDose-dependent effectNodal statusWorse prognosisPathologic stagePatient groupProgesterone receptorDurvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research